About Interpace Diagnostics Group, Inc.
Interpace Diagnostics provides molecular diagnostic tests and pathology services for evaluating risk of cancer to support better patient diagnosis and management. The Company currently has four commercialized molecular tests: PancraGen® for the evaluation of pancreatic cysts, biliary strictures, and solid lesions; ThyGeNEXT®, a NGS based test for the diagnosis of thyroid cancer from indeterminate thyroid nodules; ThyraMIR® for the diagnosis of thyroid cancer utilizing a proprietary gene expression assay; and RespriDx for differentiating between new lung tumors and metastases using proprietary molecular fingerprinting. Interpace Diagnostics has two CAP accredited and CLIA certified laboratories. The Company’s mission is to support personalized medicine through molecular diagnostics and innovation that advances patient care based on rigorous science and evidence.
300 Interpace Parkway
Morris Corporate Center 1, Bldg C
Parsippany, New Jersey 07054